Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Tr

Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

AOC 1044 is the first antibody oligonucleotide conjugate (AOC™) of multiple Duchenne muscular dystrophy programs to enter the clinicFirst AOC from...

Related Keywords

California , United States , San Diego , Ukraine , Navjot Rai , Kathleen Gallagher , Craigm Mcdonald , Sarah Boyce , University Of California , Training Center , Prnewswire Avidity Biosciences Inc , Nasdaq , Exchange Commission , Department Of Physical Medicine , Avidity Biosciences Inc , Antibody Oligonucleotide Conjugates , Physical Medicine , Neuromuscular Diseases , Oligonucleotide Conjugates , Private Securities Litigation Reform Act ,